Ethics Approval Received for SPONTAN Phase II Clinical Study

• Study expected to generate prescribing information for doctors treating men aged 65+, who are often prescribed lower doses of oral PDE5 tablets (Viagra, etc.) • Recruitment to commence Q1 CY 2026 • Initial data expected Q2 CY 2026; full results mid-2026 LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) is pleased to announce that Human Research Ethics Committee (HREC) approval has bee